By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Incyte Corporation 

Experimental Station
Route 141 & Henry Clay Road, Building E336
Wilmington  Delaware  19880  U.S.A.
Phone: 302-498-6700 Fax: 302-425-2750


Company News
Incyte Corporation (INCY) Release: Jakavi (ruxolitinib) Receives European Commission Approval As First Targeted Therapy For Patients With Polycythemia Vera 3/17/2015 11:16:25 AM
Incyte Corporation (INCY) Appoints Steven H. Stein, MD As Chief Medical Officer 3/2/2015 10:34:36 AM
Incyte Corporation (INCY) Sponsors First Observational Study Designed To Understand The Impact Of Polycythemia Vera—A Rare, Progressive Blood Cancer 2/26/2015 9:42:57 AM
Incyte Corporation (INCY) To Present At Upcoming Investor Conferences 2/17/2015 12:28:26 PM
Incyte Corporation (INCY) Reports 2014 Fourth-Quarter And Year-End Financial Results; Provides 2015 Financial Guidance; Updates Shareholders On Key Clinical Programs 2/12/2015 7:55:59 AM
Advaxis, Inc. Forms Clinical Trial Collaboration With Incyte Corporation (INCY) To Evaluate Investigational Combination Of Two Novel Cancer Immunotherapies For Early Stage Cervical Cancer 2/11/2015 7:56:49 AM
Incyte Corporation (INCY) Announces Publication Of Phase 3 RESPONSE Trial In Patients With Polycythemia Vera In New England Journal Of Medicine 1/29/2015 10:18:18 AM
Incyte Corporation (INCY) To Report Fourth Quarter/Year-End 2014 Financial Results On February 12 1/27/2015 11:15:34 AM
Incyte Corporation (INCY) Earns $25 Million Milestone As Jakavi® (ruxolitinib) Recommended For Approval In Europe For Polycythemia Vera 1/23/2015 6:26:50 AM
Incyte Corporation (INCY) Board Appoints Two New Directors 1/9/2015 9:27:48 AM